InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team
May 2, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Eva Arlander as Chief Development Officer. Eva will also be part of the management team, together with acting Chief Executive Officer and Chief Financial Officer Johan Giléus, Chief Medical Officer Anders Bröijersén and Chief Scientific Officer Charlotte Admyre.
Eva Arlander is a pharmacist and PhD in clinical pharmacology, and has previously held senior positions at Astra Zeneca, Medivir and Affibody with a main focus on clinical development, as well as department head at the Medical Products Agency.
Anders Bröijersén, who previously held the role of Senior Medical Director Clinical Operations at InDex, will take over as Chief Medical Officer after Thomas Knittel, who will continue to be engaged by the company as Senior Medical Consultant.
Charlotte Admyre has worked at InDex for many years and has held several key positions in research and development, business development and investor relations.
“I would like to welcome Eva to InDex and the management team,” said Johan Giléus, acting CEO of InDex Pharmaceuticals. “I am pleased that InDex has been able to attract such a qualified and competent person, and I am very much looking forward to working with InDex's new management team as we now take cobitolimod through phase III and towards the market.”
For more information:
Johan Giléus, Acting CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at 11:45 CET on May 2, 2022.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.
Tags: